Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study

Saved in:
Bibliographic Details
Main Authors: Chang-Yuan Hsu, Che-Wei Chang, Su-Boon Yong, Chin-Yuan Yii
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Pharmacological Research
Subjects:
Medicine
Review
SGLT2 inhibitor
Weight control
Diabetes
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825000647
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1043661825000647

Similar Items